Experts in gastrointestinal cancers review optimal treatment strategies for the management of metastatic colorectal cancer (mCRC).
EP. 1: Overview of Colorectal Cancer
Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.
EP. 2: Role of Genomic Testing in mCRC
Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.
EP. 3: Selecting Frontline Therapy for Newly Diagnosed mCRC
Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.
EP. 4: Using ICI Therapy in MSI-High mCRC
Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.
EP. 5: Role of Maintenance Therapy in Advanced CRC
Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.
EP. 6: Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC
Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.
EP. 7: Dosing Strategies for Regorafenib for Patients With mCRC
Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.
EP. 8: Management of Relapsed mCRC
Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.
EP. 9: Sequencing Therapy for Relapsed mCRC
Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.
EP. 10: Future Directions for mCRC Management
Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.